SC-58125 NEW
| Price | $35 | $77 | $119 |
| Package | 10mg | 25mg | 50mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-04 |
Product Details
| Product Name: SC-58125 | CAS No.: 162054-19-5 |
| Purity: 99.81% | Supply Ability: 10g |
| Release date: 2026/07/04 |
Product Introduction
Bioactivity
| Name | SC-58125 |
| Description | SC-58125 is a selective cyclooxygenase 2 (COX-2) inhibitor, with an IC50 of 0.04 μM. SC-58125 exhibits antitumor activity in vitro and in vivo, and it also can inhibit edema at the inflammatory site and is analgesic |
| In vitro | SC-58125 treatment on the growth of human colon carcinoma cells in nude mice.?Delaying treatment by 2, 4, or 7 weeks following implantation of the carcinoma cells resulted in a significant inhibition of tumor growth.?Furthermore, short-term (48 hours) treatment with SC-58125 was sufficient to attenuate tumor growth for up to 15 days.?SC-58125 treatment did not alter the rate at which cells underwent apoptosis, but did result in a delayed progression through the cell cycle at the G(2)/M transition.?Accordingly, p34(cdc2) protein levels and activity were decreased following SC-58125 treatment.SC-58125 primarily exerts a cytostatic effect in vivo, which is likely to be mediated through inhibition of progression through the G(2)/M phase of the cell cycle |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 9 mg/mL (23.42 mM), Sonication is recommended. |
| Keywords | SC-58125 | SC58125 | Inhibitor | inhibit | inflammatory | edema | Cyclooxygenase | COX-2 | COX | cancer | antitumor |
| Inhibitors Related | Naproxen sodium | Acetaminophen | Phenidone | 4-Aminosalicylic acid | Gallic Acid Monohydrate | Diclofenac Potassium | Indomethacin | Paradol | Trometamol | 5-Methylfurfural | Phenylbutazone | Magnesium sulfate |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | ReFRAME Related Library | Pyroptosis Compound Library | Angiogenesis related Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2180.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-06-11 | |
| $700.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
| $2.00 |
VIP2Y
|
ZHENGZHOU JIUYI TIME NEW MATERIALS CO,.LTD
|
2026-07-02 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY